



PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

#ICYMI - Perimeter is Featured in *BioTuesdays*

We are excited to be featured in the [BioTuesdays newsletter](#). Adrian Mendes, Perimeter's CEO and Andrew Berkeley, Perimeter's CIO spoke about our company mission and vision, and how and why we seek to innovate medical imaging.

"Perimeter's Optical Coherence Tomography (OCT) technology aims to offer surgeons the most advanced intraoperative margin visualization available, providing clarity on margin status right in the OR versus waiting, sometimes days, for pathology results."

Adrian Mendes
CEO, Perimeter Medical Imaging AI

BIOTUESDAYS

The article expands upon why there is a real unmet need to provide surgeons with technologies to assist with intraoperative margin assessment.

A portrait of Andrew Berkeley, a man with short brown hair and a light blue shirt under a dark blue blazer, smiling slightly. The background is a solid red color.

"Intraoperative margin assessment is one of the most pressing issues for cancer surgeons. Perimeter's mission is to provide them with real-time insights to help make critical decisions, potentially reducing re-excisions, minimizing patient trauma, and saving healthcare costs."

Andrew Berkeley
Chief Innovation Officer,
Perimeter Medical Imaging AI

BIOTUESDAYS 

Adrian also speaks about several longer-term platform expansion opportunities for the company. [Read full article here.](#)

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- **X** (formerly Twitter): <https://twitter.com/PerimeterMed>
- **LinkedIn**: <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

This information is intended for an investor audience and not for use by healthcare professionals. The information contained herein should not be used to guide clinical practice.

S-Series OCT

The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest.

The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates.

The safety and effectiveness of these uses has not been established.

For full information on unapproved/off-label uses, visit: perimetermed.com/disclosures or contact medicalaffairs@perimetermed.com.

B-Series OCT

The Perimeter B-Series OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection

algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. Selene is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

Perimeter B-Series OCT is not available for sale in the United States. CAUTION – Investigational device. Limited by U.S. law to investigational use

*You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the **"Unsubscribe Preferences"** link below if you wish to opt out of this e-newsletter.*



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.